Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

The autophagy protein ATG9A promotes HIV-1 infectivity.

Mailler E, Waheed AA, Park SY, Gershlick DC, Freed EO, Bonifacino JS.

Retrovirology. 2019 Jul 3;16(1):18. doi: 10.1186/s12977-019-0480-3.

2.

TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins.

Li M, Waheed AA, Yu J, Zeng C, Chen HY, Zheng YM, Feizpour A, Reinhard BM, Gummuluru S, Lin S, Freed EO, Liu SL.

Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5705-5714. doi: 10.1073/pnas.1819475116. Epub 2019 Mar 6.

PMID:
30842281
3.

Myosin-X is essential to the intercellular spread of HIV-1 Nef through tunneling nanotubes.

Uhl J, Gujarathi S, Waheed AA, Gordon A, Freed EO, Gousset K.

J Cell Commun Signal. 2019 Jun;13(2):209-224. doi: 10.1007/s12079-018-0493-z. Epub 2018 Nov 15.

4.

Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials.

Riaz H, Khan MS, Schenone AL, Waheed AA, Khan AR, Krasuski RA.

Am Heart J. 2018 May;199:44-50. doi: 10.1016/j.ahj.2018.01.008. Epub 2018 Jan 31. Review.

PMID:
29754665
5.

Fibrolipomatous Hamartoma of the Median Nerve with Macrodystrophia Lipomatosa.

Azeemuddin M, Waheed AA, Khan N, Sayani R, Ahmed A.

Cureus. 2018 Mar 9;10(3):e2293. doi: 10.7759/cureus.2293.

6.

Bursal Synovial Chondromatosis Secondary to Underlying Osteochondroma in a Child.

Khandwala K, Waheed AA, Alvi MI, Mirza WA, Umer M, Khurshid E.

Cureus. 2017 Dec 14;9(12):e1944. doi: 10.7759/cureus.1944.

7.

High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release.

Waheed AA, Gitzen A, Swiderski M, Freed EO.

Viruses. 2018 Jan 5;10(1). pii: E26. doi: 10.3390/v10010026.

8.

The Vpu-interacting Protein SGTA Regulates Expression of a Non-glycosylated Tetherin Species.

Waheed AA, MacDonald S, Khan M, Mounts M, Swiderski M, Xu Y, Ye Y, Freed EO.

Sci Rep. 2016 Apr 22;6:24934. doi: 10.1038/srep24934.

9.

Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Martins AN, Waheed AA, Ablan SD, Huang W, Newton A, Petropoulos CJ, Brindeiro RD, Freed EO.

J Virol. 2015 Oct 28;90(2):768-79. doi: 10.1128/JVI.01640-15. Print 2016 Jan 15.

10.

Why Do We Need New Drug Classes for HIV Treatment and Prevention?

Waheed AA, Tachedjian G.

Curr Top Med Chem. 2016;16(12):1343-9. Review.

PMID:
26459806
11.

Current and Emerging Drug Targets for Human Immunodeficiency Virus.

Waheed AA, Tachedjian G.

Curr Top Med Chem. 2016;16(10):1072-3. No abstract available.

PMID:
26381413
12.

Is it time to replace propranolol with carvedilol for portal hypertension?

Abid S, Ali S, Baig MA, Waheed AA.

World J Gastrointest Endosc. 2015 May 16;7(5):532-9. doi: 10.4253/wjge.v7.i5.532. Review.

13.

Vivax malaria and chloroquine resistance: a neglected disease as an emerging threat.

Waheed AA, Ghanchi NK, Rehman KA, Raza A, Mahmood SF, Beg MA.

Malar J. 2015 Apr 8;14:146. doi: 10.1186/s12936-015-0660-0.

14.

In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity.

Waheed AA, Kuruppu ND, Felton KL, D'Souza D, Freed EO.

PLoS One. 2014 Oct 31;9(10):e111628. doi: 10.1371/journal.pone.0111628. eCollection 2014.

15.

HIV-1 Vpu accessory protein induces caspase-mediated cleavage of IRF3 transcription factor.

Park SY, Waheed AA, Zhang ZR, Freed EO, Bonifacino JS.

J Biol Chem. 2014 Dec 19;289(51):35102-10. doi: 10.1074/jbc.M114.597062. Epub 2014 Oct 28.

16.

Lupus vasculopathy: Diagnostic, pathogenetic and therapeutic considerations.

Gonzalez-Suarez ML, Waheed AA, Andrews DM, Ascherman DP, Zeng X, Nayer A.

Lupus. 2014 Apr;23(4):421-7. doi: 10.1177/0961203313520340. Epub 2014 Jan 22.

PMID:
24452079
17.

Dual-acting stapled peptides target both HIV-1 entry and assembly.

Zhang H, Curreli F, Waheed AA, Mercredi PY, Mehta M, Bhargava P, Scacalossi D, Tong X, Lee S, Cooper A, Summers MF, Freed EO, Debnath AK.

Retrovirology. 2013 Nov 15;10:136. doi: 10.1186/1742-4690-10-136.

18.

Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.

Daniels SI, Soule EE, Davidoff KS, Bernbaum JG, Hu D, Maeda K, Stahl SJ, Naiman NE, Waheed AA, Freed EO, Wingfield P, Yarchoan R, Davis DA.

FASEB J. 2014 Jan;28(1):106-16. doi: 10.1096/fj.13-238113. Epub 2013 Oct 4.

19.

Phosphate control in end-stage renal disease: barriers and opportunities.

Waheed AA, Pedraza F, Lenz O, Isakova T.

Nephrol Dial Transplant. 2013 Dec;28(12):2961-8. doi: 10.1093/ndt/gft244. Epub 2013 Jul 30. Review.

20.

Blood pressure recordings during hemodialysis access interventions: implications for acute management.

Asif A, Castro H, Waheed AA, Kumar V, Haqqie SS, Siskin G, Mathew RO, Mason D, Vachharajani T, Nayer A, Merrill D, Akmal MU, Salman L.

Semin Dial. 2013 Jul-Aug;26(4):E30-2. doi: 10.1111/sdi.12083. Epub 2013 Mar 28.

PMID:
23551213
21.

Host-pathogen interactions of retroviruses.

Waheed AA, Brass AL, Gummuluru S, Tachedjian G.

Mol Biol Int. 2012;2012:648512. doi: 10.1155/2012/648512. Epub 2012 Oct 24. No abstract available.

22.

Lupus nephritis: maintenance therapy for lupus nephritis--do we now have a plan?

Lenz O, Waheed AA, Baig A, Pop A, Contreras G.

Clin J Am Soc Nephrol. 2013 Jan;8(1):162-71. doi: 10.2215/CJN.03640412. Epub 2012 Aug 23. Review.

23.

HIV type 1 Gag as a target for antiviral therapy.

Waheed AA, Freed EO.

AIDS Res Hum Retroviruses. 2012 Jan;28(1):54-75. doi: 10.1089/AID.2011.0230. Epub 2011 Sep 21. Review.

24.

Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.

Kim SE, Liu F, Im YJ, Stephen AG, Fivash MJ, Waheed AA, Freed EO, Fisher RJ, Hurley JH, Burke TR Jr.

ACS Med Chem Lett. 2011 May 12;2(5):337-341.

25.

Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain.

Zhang H, Curreli F, Zhang X, Bhattacharya S, Waheed AA, Cooper A, Cowburn D, Freed EO, Debnath AK.

Retrovirology. 2011 May 3;8:28. doi: 10.1186/1742-4690-8-28.

26.

Combination approaches to potentiate immune response after photodynamic therapy for cancer.

St Denis TG, Aziz K, Waheed AA, Huang YY, Sharma SK, Mroz P, Hamblin MR.

Photochem Photobiol Sci. 2011 May;10(5):792-801. doi: 10.1039/c0pp00326c. Epub 2011 Apr 9. Review.

27.

The Role of Lipids in Retrovirus Replication.

Waheed AA, Freed EO.

Viruses. 2010 May 1;2(5):1146-1180.

28.

Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail.

Waheed AA, Ablan SD, Sowder RC, Roser JD, Schaffner CP, Chertova E, Freed EO.

J Virol. 2010 Mar;84(6):3121-6. doi: 10.1128/JVI.02002-09. Epub 2009 Dec 30.

29.

Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.

Liu F, Stephen AG, Waheed AA, Freed EO, Fisher RJ, Burke TR Jr.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):318-21. doi: 10.1016/j.bmcl.2009.10.105. Epub 2009 Oct 29.

30.

Lipids and membrane microdomains in HIV-1 replication.

Waheed AA, Freed EO.

Virus Res. 2009 Aug;143(2):162-76. doi: 10.1016/j.virusres.2009.04.007. Epub 2009 Apr 19. Review.

31.

Peptide inhibitors of HIV-1 egress.

Waheed AA, Freed EO.

ACS Chem Biol. 2008 Dec 19;3(12):745-7. doi: 10.1021/cb800296j.

PMID:
19099395
32.

Methods for the study of HIV-1 assembly.

Waheed AA, Ono A, Freed EO.

Methods Mol Biol. 2009;485:163-84. doi: 10.1007/978-1-59745-170-3_12.

PMID:
19020825
33.

SAR by oxime-containing peptide libraries: application to Tsg101 ligand optimization.

Liu F, Stephen AG, Waheed AA, Aman MJ, Freed EO, Fisher RJ, Burke TR Jr.

Chembiochem. 2008 Aug 11;9(12):2000-4. doi: 10.1002/cbic.200800281.

34.

Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence.

Waheed AA, Ablan SD, Soheilian F, Nagashima K, Ono A, Schaffner CP, Freed EO.

J Virol. 2008 Oct;82(19):9776-81. doi: 10.1128/JVI.00917-08. Epub 2008 Jul 23.

35.

A cell-penetrating helical peptide as a potential HIV-1 inhibitor.

Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK.

J Mol Biol. 2008 May 2;378(3):565-80. doi: 10.1016/j.jmb.2008.02.066. Epub 2008 Mar 6.

36.

Influenza virus not cRAFTy enough to dodge viperin.

Waheed AA, Freed EO.

Cell Host Microbe. 2007 Aug 16;2(2):71-2.

37.
38.

HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.

Waheed AA, Ablan SD, Roser JD, Sowder RC, Schaffner CP, Chertova E, Freed EO.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8467-71. Epub 2007 May 4.

39.

Proteomic of lipid rafts in the exocrine pancreas from diet-induced obese rats.

Berkane AA, Nguyen HT, Tranchida F, Waheed AA, Deyris V, Tchiakpe L, Fasano C, Nicoletti C, Desseaux V, Ajandouz el H, Comeau D, Comeau L, Hiol A.

Biochem Biophys Res Commun. 2007 Apr 13;355(3):813-9. Epub 2007 Feb 15.

PMID:
17320817
40.
41.

Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants.

Waheed AA, Ablan SD, Mankowski MK, Cummins JE, Ptak RG, Schaffner CP, Freed EO.

J Biol Chem. 2006 Sep 29;281(39):28699-711. Epub 2006 Aug 1.

42.

Perfringolysin O, a cholesterol-binding cytolysin, as a probe for lipid rafts.

Ohno-Iwashita Y, Shimada Y, Waheed AA, Hayashi M, Inomata M, Nakamura M, Maruya M, Iwashita S.

Anaerobe. 2004 Apr;10(2):125-34.

PMID:
16701509
43.

Proteomic characterization of lipid rafts markers from the rat intestinal brush border.

Nguyen HT, Amine AB, Lafitte D, Waheed AA, Nicoletti C, Villard C, Létisse M, Deyris V, Rozière M, Tchiakpe L, Danielle CD, Comeau L, Hiol A.

Biochem Biophys Res Commun. 2006 Mar 31;342(1):236-44. Epub 2006 Feb 6.

PMID:
16480947
44.

Separation of a cholesterol-enriched microdomain involved in T-cell signal transduction.

Shimada Y, Inomata M, Suzuki H, Hayashi M, Waheed AA, Ohno-Iwashita Y.

FEBS J. 2005 Nov;272(21):5454-63.

46.

Citation rate unrelated to journals' impact factors.

Waheed AA.

Nature. 2003 Dec 4;426(6966):495. No abstract available.

PMID:
14654813
47.

RGS16 inhibits signalling through the G alpha 13-Rho axis.

Johnson EN, Seasholtz TM, Waheed AA, Kreutz B, Suzuki N, Kozasa T, Jones TL, Brown JH, Druey KM.

Nat Cell Biol. 2003 Dec;5(12):1095-103. Epub 2003 Nov 23.

PMID:
14634662
48.

Cellular aging-dependent decrease in cholesterol in membrane microdomains of human diploid fibroblasts.

Nakamura M, Kondo H, Shimada Y, Waheed AA, Ohno-Iwashita Y.

Exp Cell Res. 2003 Nov 1;290(2):381-90.

PMID:
14567995
49.

Concentration of rafts in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains.

Heijnen HF, Van Lier M, Waaijenborg S, Ohno-Iwashita Y, Waheed AA, Inomata M, Gorter G, Möbius W, Akkerman JW, Slot JW.

J Thromb Haemost. 2003 Jun;1(6):1161-73.

50.

Scientists turn to journals in English.

Waheed AA.

ScientificWorldJournal. 2001 Jun 16;1:239-40.

Supplemental Content

Loading ...
Support Center